You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 Negative Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Tucson (Rucaparib)

Active, not recruiting
  • Breast Cancer
  • Tucson, Arizona
    University of Arizona Cancer Center
Feb 24, 2022

Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

Withdrawn
  • Urothelial Carcinoma
  • +4 more
  • (no location specified)
Apr 4, 2022

Solid Tumor, Breast Cancer, Small Cell and NSCLC Trial in Hackensack (RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior

Recruiting
  • Solid Tumor
  • +15 more
  • RAPA-201 Rapamycin Resistant T Cells
  • Chemotherapy Prior to RAPA-201 Therapy
  • Hackensack, New Jersey
    Hackensack University Medical Center
Dec 23, 2021

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 2, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Gastrointestinal Tumors Trial in Beijing (68Ga-WL12 PET/CT)

Recruiting
  • Gastrointestinal Tumors
  • 68Ga-WL12 PET/CT
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 18, 2022

Lung Cancer Trial (QL1706, Tilesizumab)

Not yet recruiting
  • Lung Cancer
  • (no location specified)
Jan 10, 2023

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,

Withdrawn
  • Triple Negative Breast Cancer
  • +4 more
  • Aurora, Colorado
    University of Colorado Hospital
Dec 2, 2022

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 26, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Efficacy, Safety Trial (PD-L1 inhibitor)

Not yet recruiting
  • Efficacy
  • Safety
  • PD-L1 inhibitor
  • (no location specified)
Apr 6, 2022

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Advanced Solid Tumors Trial in China (IMM2510)

Recruiting
  • Advanced Solid Tumors
  • Luoyang, Henan, China
  • +3 more
Jul 25, 2023

Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,

Not yet recruiting
  • Lung Cancer
  • +3 more
  • Kansas City, Kansas
  • +3 more
May 12, 2023